EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and safety of alirocumab and evolocumab for hypercholesterolemia in a population with high cardiovascular risk

Montserrat Bosch, Immaculada Danés, Elena Ballarín, Patricia Marrero, Guillem Vancells, Ángel Ortiz-Zúñiga, Maria Urquizu-Padilla, Nuria Rial-Lorenzo, Jordi Lozano-Torres, David Rodríguez-Luna, Francesca Filippi-Arriaga, Antònia Agustí

Medicina Clínica · 2024-10 · 163 (7) · 317-322

DOI: 10.1016/j.medcli.2024.05.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina Clínica, 2024-10. Verfasst von Montserrat Bosch und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Department of Pharm…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hypercholesterolemia, Cardiovascular Diseases, PCSK9 Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHypercholesterolemiaCardiovascular DiseasesPCSK9 InhibitorsAnticholesteremic AgentsCholesterol, LDLHumansMaleFemaleRetrospective StudiesMiddle AgedAgedTreatment OutcomeHeart Disease Risk FactorsProprotein Convertase 9

Stichwörter der Autor:innen

Acontecimientos cardiovascularesCardiovascular eventsDrug utilizationHipercolesterolemiaHypercholesterolemiaInhibidores de PCSK9Lipoproteínas de baja densidadLow-density lipoproteinsPCSK9 inhibitorsUtilización de fármacos

Substanzen

Antibodies, Monoclonal, HumanizedalirocumabevolocumabPCSK9 InhibitorsAnticholesteremic AgentsCholesterol, LDLPCSK9 protein, humanProprotein Convertase 9

Autor:innen und Institutionen

  • Clinical Pharmacology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelon…
  • Clinical Pharmacology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Clinical Pharmacology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'He…
  • Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Endocrinology and Nutrition Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Internal Medicine Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Cardiology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Zitieren

APA

Bosch, M., Danés, I., Ballarín, E., Marrero, P., Vancells, G., Ortiz-Zúñiga, Á., Urquizu-Padilla, M., Rial-Lorenzo, N., Lozano-Torres, J., Rodríguez-Luna, D., Filippi-Arriaga, F., & Agustí, A. (2024). Effectiveness and safety of alirocumab and evolocumab for hypercholesterolemia in a population with high cardiovascular risk. Medicina Clínica, 163(7), 317-322. https://doi.org/10.1016/j.medcli.2024.05.004

Vancouver

Bosch M, Danés I, Ballarín E, Marrero P, Vancells G, Ortiz-Zúñiga Á, et al. Effectiveness and safety of alirocumab and evolocumab for hypercholesterolemia in a population with high cardiovascular risk. Medicina Clínica. 2024;163(7):317-322. doi:10.1016/j.medcli.2024.05.004

BibTeX
@article{Bosch2024,
  author = {Bosch, Montserrat and Danés, Immaculada and Ballarín, Elena and Marrero, Patricia and Vancells, Guillem and Ortiz-Zúñiga, Ángel and Urquizu-Padilla, Maria and Rial-Lorenzo, Nuria and Lozano-Torres, Jordi and Rodríguez-Luna, David and Filippi-Arriaga, Francesca and Agustí, Antònia},
  title = {Effectiveness and safety of alirocumab and evolocumab for hypercholesterolemia in a population with high cardiovascular risk},
  journal = {Medicina Clínica},
  year = {2024},
  volume = {163},
  number = {7},
  pages = {317--322},
  doi = {10.1016/j.medcli.2024.05.004}
}
Kostenlos starten →